INTRODUCTION R
esin-containing materials are used routinely in dental practice as direct filling materials, fissure sealing agents, bonding resins, and resin cements. Among the components of most bonding and restorative resins are: (1) a primary resin, usually bisphenol-A-glycidyldimethacrylate (BisGMA); and (2) triethyleneglycoldimethacrylate (TEGDMA), which is included to compensate for the high viscosity of the primary resin. Resin composites contain BisGMA in amounts varying from 5-9 wt% (Munksgaard et al., 2000) , while fissure sealants contain BisGMA in the range 10-50% (Komurcuoglu et al., 2005) .
Direct evidence of BisGMA release from composite resins and fissure sealants into the biophase was provided previously (Tanaka et al., 1991; Spahl et al., 1998; Nalcaci et al., 2006) . Released dental material components can be expected to enter the body by 2 different routes after resin placement, via the saliva and gastrointestinal tract, plus (if the material is placed on dentin) via the dentin and pulp (Hume and Gerzina, 1996) .
To test the hypothesis that BisGMA reaches cytotoxic levels in body tissues, and to develop an understanding of the whole-body kinetics of BisGMA, we measured the uptake, distribution, and clearance of [ 14 C]BisGMA administered by gastric tube and by intravenous injection in guinea pigs.
MATERIALS & METHODS
[ 14 C]BisGMA was purchased from Perkin Elmer (Boston, MA, USA), dissolved in dichloromethane, and stored at -20°C. Unlabeled BisGMA was obtained from Degussa (Frankfurt, Germany).
In situ Experiments
Guinea pigs were randomized and allotted to 3 groups of 4 animals each. The animals were anesthetized with urethane (1 mg/kg, 4 mL/kg; dissolved in 0.9% NaCl solution). The ductus cysticus was ligated, and a cannula was placed in the bile duct, as described in previous experiments (Reichl et al., 2001) . A 1 mL/kg quantity of BisGMA, dissolved in DMSO (final DMSO concentration, 1%), was injected via the jugular vein [0.02 mol/kg body weight (bw), labeled with a tracer dose of [ 14 C]BisGMA, 0.3 kBq/g bw] (group 1). Control animals (groups 2 and 3) received either 0.9% NaCl solution or DMSO (final DMSO concentration, 1% in 0.9% NaCl solution), each without BisGMA. Blood was withdrawn from the carotid artery. Samples of the bile (0.4 mL) and blood (0.2 mL) were taken every 10 min. The experimental period was 60 min. The organs and their contents were immediately removed and their [ 14 C]-radioactivity measured.
In vivo Experiments
Adult male guinea pigs (Dunkin-Hartley Pirbright white strain, 400 g), were fed a standard diet and water ad libitum. Twelve guinea pigs were allotted to 3 groups of 4 animals each. Each animal was put into a separate metabolic cage 3 days before and food was removed 12 hrs before the experiment. Each animal
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Distribution of BisGMA in Guinea Pigsreceived BisGMA (0.02 mol/kg bw, dissolved 1% DMSO solution, labeled with a tracer dose of [ 14 C]BisGMA, 0.3 kBq/g bw) via gastric tube (group 4). Control animals (groups 5 and 6) received either 0.9% NaCl solution or DMSO (final DMSO concentration, 1%), each without BisGMA. The volume for the application through the gastric tube was 4 mL/kg. Feces and urine were collected at 1, 2, 4, 6, 8, 12, and 24 hrs after [ 14 C]BisGMA administration, and the [ 14 C]-radioactivity was measured as described below. Twenty-four hrs after the beginning of the experiment, the animals were killed in ether. The organs and their contents were immediately removed and their [ 14 C]-radioactivity measured. Details of organ treatment and the method of determination of radioactivity are in the APPENDIX. Data are presented as means ± SEM. Statistical significance of the differences between the experimental groups was determined by the Bonferroni-Holm t test (Sheskin, 2007) .
A second set of 12 guinea pigs was treated as described above, with the addition that each animal was kept in a closed chamber with controlled air flow. The exhaled air was captured during the 24-hour experimental period by flowing through 7 bottles, 1 behind the other, filled with 250 mL ice-cold 5 N NaOH (see Fig.) . [ 14 C]-carbon dioxide was captured as [ 14 C]-Na 2 CO 3 and the total [ 14 C] activity determined. Urine and feces were collected at 24 hrs after the beginning of the experiment, and the animals were killed and organs taken for analysis as described for the first in vivo experimental group.
Declaration
These experiments complied with the current laws of Germany. The animal experiments were approved by the Regierung von Oberbayern, permission no. 211-2531-66/94.
The accession number for 14 C compounds is: 4/4-8816.352-14783, Bayerisches Landesamt für Umweltschutz, Augsburg, Germany.
Guinea Pig Organs
Organs taken and tested were: liver, kidney, blood, skin, brain, heart, spleen, lung, muscle, testes, eyes, bone, nerve tissue, spinal cord, wall of stomach, content of stomach, wall of ileum + jejunum, content of ileum + jejunum, wall of colon, content of colon, wall of caecum, content of caecum, wall of gall bladder, and fat tissue. Organs were immediately washed with 2 x 10 mL distilled H 2 O, the wash-water was saved, and then the tissues were weighed and homogenized.
Determination of Radioactivity, Guinea Pig Experiments
Tissues were dissolved in tetraethylammoniumhydroxide (TEAH) (20%) in aqueous solution with Omni-Szintisol ® (both from Merck, Darmstadt, Germany). Radioactivity was determined by the method described by Strugala (1984) , with a liquid scintillation counter (2500 TR, Canberra-Packard, Dreieich, Germany).
RESULTS [ 14 C] Recovery from Guinea Pigs after 1 Hr
During the first hr after [ 14 C]BisGMA intravenous injection, about 12% of the [ 14 C] was excreted via the bile, and about 50% remained in the tissues at 1 hr, the time the guinea pigs were killed (Table 1) . [ 14 C] activity was rapidly removed from the blood (Table 1) . Additional data on [ 14 C] distribution in the bile and blood and [ 14 C] activity in various organs are included in the APPENDIX.
[ 14 C] Recovery from Guinea Pigs after 24 Hrs
During the first 24 hrs after [ 14 C]BisGMA oral administration, guinea pigs exhaled 14 CO 2 equivalent to about 65% of the [ 14 C]BisGMA dose administered (Table 2) . About 7% of the [ 14 C] was excreted via urine, and about 6% remained in the tissues at 24 hrs, the time the guinea pigs were killed ( 
DISCUSSION
The administered dose levels were chosen to exceed substantially the body-weight-adjusted dose levels relative to humans for BisGMA released from large composite resin restorations. For the guinea pig experiments, we used the data of Munksgaard et al. (2000) , who measured extracted quantities from polymerized composites eluted for 7 days with water. The values for various composite components eluted in these chemical experiments ranged from 0.03 to 0.07 wt% in water. The highest eluted BisGMA level into water shown by Munksgaard et al. (2000) was from the commercial composite Z100 ® (3M ESPE, Seefeld, Germany), which provided about 1.5 mol BisGMA from 16 g composite. Assuming the worst case, that all restorations in all teeth are replaced by Z100 (32 teeth; about 0.5 grams per tooth/filling = about 16 g Z100), a dose level equivalent to the total amount released from this material was used and adjusted by proportion with the body weight of the average human (1.5 mol BisGMA/70 kg bw = 0.02 mol/kg bw). Analysis of our data showed that uptake of [ 14 C]BisGMA from the stomach and intestine of guinea pigs was rapid and essentially complete, and that distribution of [ 14 C]BisGMA and/or its metabolites throughout the body with these routes of administration was broad. More than 65% of the administered [ 14 C] was excreted via the lungs as 14 CO 2 in guinea pigs, while some 7% of the administered [ 14 C] appeared in the urine. Most of the [ 14 C] label was cleared from the body one day following gastric administration.
The cumulative biliary [ 14 C] excretion was about 2 times higher after 60 min than the cumulative fecal [ 14 C] excretion after 24 hrs. Therefore, enterohepatic recycling of [ 14 C]BisGMA and/or [ 14 C]BisGMA metabolite(s) cannot be excluded. Enterohepatic recycling and similar biological clearances have also been described for HEMA and TEGDMA in guinea pigs (Reichl et al., 2001 (Reichl et al., , 2002 . Analysis of the present data indicates the existence of similar mechanisms for uptake and biliary excretion for HEMA, TEGDMA, and BisGMA.
We did not determine where, in the organism, BisGMA was metabolized to carbon dioxide. However, the moderately elevated levels in the lung relative to other tissues after intravenous or oral administration suggest metabolic conversion in that tissue. Furthermore, metabolism of BisGMA and formation of CO 2 from BisGMA appear to be independent of these routes of administration, i.e., metabolism of BisGMA in the stomach and/or in the intestine is very unlikely. Further discussion about possible metabolic pathways and distribution and clearance following intravenous and oral administration is included in the APPENDIX.
Despite the fact that the body-weight-adjusted dose of BisGMA administered was more than 20 times higher than that which would be encountered by a human, the highest levels of BisGMA observed in tissue samples taken from guinea pigs, 1.5 nano M in the lung, 1 hr after intraveneous injection are approximately 1000-fold less than the known toxic level for BisGMA (Kostoryz et al., 2003; Schwengberg et al., 2005; Reichl et al., 2006; Schweikl et al., 2006) . Similarly, with a dose well in excess of the weightadjusted, expected equivalent in humans, the highest [ 14 C] concentration in the spontaneous urine in guinea pigs was found 4 hrs after the oral [ 14 C] application (1.2% in 1.4 mL). Peak levels in blood and kidney tissue occurred much earlier than this, which is consistent with the known time dynamics of urine production and the variable (but expected) delay before urine release. Calculated from this [ 14 C] peak concentration in the urine at the dose administered, a peak BisGMA concentration in the spontaneous urine can be estimated at about 0.2 nmol/L. This concentration is at least 1/500,000th of the level that decreased the cell survival ratio in kidney cells (Hikage et al., 1999) . It is therefore unlikely that BisGMA released from restorative materials could have any systemic, toxic effects. However, it is noted that only general cytotoxic effects were investigated in association with BisGMA, and there may be many as-yet-uninvestigated toxic effects generated in various cells by this substance.
The possibility of allergic responses in patients and in dental workers is discussed in the APPENDIX.
